Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Fractyl Health, Inc. - Common Stock
(NQ:
GUTS
)
3.010
+0.100 (+3.44%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Fractyl Health, Inc. - Common Stock
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 14, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure
August 08, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024
August 07, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
July 30, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
June 25, 2024
Company will discuss recent corporate updates, including compelling preclinical data from Rejuva® pancreatic gene therapy platform, which was named top abstract at American Diabetes Association’s 84th...
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
June 24, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s
June 23, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
May 29, 2024
Management to host in-person KOL event and webcast at ADA on Monday, June 24, 2024, at 7:00 a.m. ET
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
May 20, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
May 13, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
May 08, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
May 07, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
April 30, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
April 02, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 01, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
April 01, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
March 12, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
March 12, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
February 20, 2024
From
Fractyl Health, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.